[Natural killer (NK) activity in patients with HIV infection]

Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.

[Natural killer (NK) activity in patients with HIV infection]

Boll Ist Sieroter Milan. 1988;67(2):135-41. Unique Identifier : AIDSLINE MED/89150059
Ortona L; Tamburrini E; Tumbarello M; Ventura G; Cauda R; Universita Cattolica del Sacro Cuore, Facolta di Medicina e; Chirurgia.

Abstract: NK activity and cells with NK phenotype (CD16+) were studied in 21 patients with HIV infection. In particular 8 patients with full-blown AIDS, 6 with AIDS related complex (ARC), 7 asymptomatic seropositive for anti-HIV antibodies were evaluated. Six subjects seronegative for anti-HIV antibodies from groups at risk for HIV infection were evaluated as well. NK activity was significantly reduced in AIDS and ARC patients but normal in asymptomatic seropositive subjects and in seronegative subjects at risk. NK cells (CD16+) were normal in AIDS patients, and in asymptomatic seropositive subjects, increased in ARC patients and in the subjects at risk. No statistical correlation was evident between the NK activity and the number of CD16+ cells in individual patients. The percentage of CD16+ cells coexpressing the HLA-DR marker i.e. CD16+ HLADR+ cells was significantly elevated only in ARC patients, and normal in the others. NK activity is the first line of defense against an invading virus and plays an important role in the immune surveillance of neoplasms. Therefore the reduced NK activity in AIDS and ARC patients can be consistent with the development of viral infections and unusual neoplasms frequently observed in such patients. The lack of correlation between defective NK activity and normal or increased number of cells with NK phenotype seems to indicate the existence of a more profound alteration in the function of NK cells rather than a simple numeric variation.

Keywords: Acquired Immunodeficiency Syndrome/*IMMUNOLOGY Adult AIDS-Related Complex/IMMUNOLOGY Cytotoxicity, Immunologic English Abstract Female Human HIV Seropositivity/IMMUNOLOGY HLA-DR Antigens/*IMMUNOLOGY Killer Cells, Natural/*IMMUNOLOGY Male JOURNAL ARTICLE

890630
M8960541

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .